Evaluating the Effectiveness of First Line Antidepressants in the Treatment of MDD

Summary

Join Dr. Adam Meadows in this compelling on-demand teaching session, titled "Red pill or blue pill: Evaluating the effectiveness of first-line antidepressants in the treatment of Major Depressive Disorder". Dr. Meadows uses a case study approach - 'Sally', a 44 y/o female Haitian immigrant - for discussing topics around treatment planning, including medication selection, Cognitive Behavioral Therapy, return-to-work planning, and the use of transcranial magnetic stimulation. Learn about patient-specific factors for medication selection, indicators of early treatment response, and methods for tracking progress. This insightful session is a must for medical professionals aiming to deepen their understanding of treating Major Depressive Disorder. It provides detailed information which will affirm or elevate your current practice.

Generated by MedBot

Description

This program is funded by an independent grant from Takeda. This online education program has been designed solely for healthcare professionals in the USA. The content is not available for healthcare professionals in any other country.

This accredited online CME course enhances the expertise of psychiatrists and healthcare professionals in managing MDD. It covers three key areas:

Evaluate First-Line Antidepressant Treatments: Learn the latest updates through comparisons of efficacy profiles. Assess patient-specific factors to choose the most appropriate treatment and identify early markers of treatment success or failure.

Enhance Patient Engagement and Education: Improve communication techniques to discuss MDD diagnosis and treatment plans. Empower patients through shared decision-making, realistic expectations, and self-monitoring strategies. Overcome adherence barriers with tailored interventions and technology support.

Promote Health Equity in MDD Treatment: Address disparities in diagnosis and treatment among underserved communities. Customize treatment plans to meet the cultural and socioeconomic needs of minority and marginalized populations, incorporating culturally sensitive practices into patient care and counseling.

Participants will gain advanced knowledge and practical skills to improve MDD management, patient engagement, and health equity in clinical practice.

Who is this course for

This online education program has been designed solely for healthcare professionals in the USA. The course provides continuing education for:

✅ Psychiatrists

✅ Psychiatry Physician Assistants

✅ Psychiatric Nurse Practitioners

✅ Clinical Psychologists

✅ Neurologists

✅ Family Physicians

✅ Physicians

✅ Physician Assistants

✅ Nurse Practitioners

✅ Other Health Professionals

Faculty

Dr Sagar Parikh

Dr. Sagar V. Parikh, MD, FRCPC, is an expert in depression and clinical neuroscience, currently holding the John F. Greden Professorship at the University of Michigan. He also serves as an adjunct Professor of Psychiatry at the University of Toronto. He started his medical career as a primary care physician before completing his Psychiatry residency at the University of Michigan and the University of Toronto. Dr. Parikh's extensive research interests include clinical trials, psychopharmacology, psychotherapy for mood disorders, medical education, epidemiology, biomarkers, interventional psychiatry, and health services. He has co-authored all ten editions of the CANMAT guidelines for depression and bipolar disorder and has published over 200 peer-reviewed articles. A renowned CME presenter and researcher, Dr. Parikh has earned numerous awards for his research and teaching at local, national, and international levels.

Dr Glenda Wrenn Gordon

Dr Glenda Wrenn Gordon is an Associate Professor of Clinical Psychiatry at Morehouse School of Medicine, Medical Director of Clinical Integration at Mindoula, and a member of the NAMI Board of Directors. She is a board-certified adult psychiatrist and a leader in advancing mental health equity. She was the founding director of the Kennedy Satcher Center for Mental Health Equity and has authored numerous publications, including recent work on racial disparities in depression treatment. In 2020, she received the NAMI Psychiatrist of the Year Award.

Dr Adam Meadows

Dr. Adam Meadows is a board-certified psychiatrist with expertise in mood disorders, adult ADHD, and mental health issues. He is Medical Director of Admissions and Adjunct Assistant Professor at Emory University School of Medicine. Dr. Meadows is a member of the American Psychiatric Association and the Georgia Psychiatric Physicians Association. Dr. Meadows completed his psychiatry residency at the University of Pennsylvania, serving as chief resident in his final year. He focuses on leadership development, public speaking, and reducing mental health stigma, aiming to make a positive societal impact.

Faculty, planners, and staff disclosure information

Sagar Parikh has consulted for Sage, Otsuka, and Aifred (software). He has received clinical trial contracts from Sage, Janssen, Compass and Aifred (software). Glenda Wrenn Gordon, Adam Meadows & Jade Brown have no relevant financial or non-financial interests to disclose.

Current Concepts Institute/MedAll staff and the planners and reviewers of this educational activity have no relevant financial or non-financial interests to disclose.

All relevant financial relationships listed for these individuals have been mitigated.

Unapproved and/or off-label use disclosure

Current Concepts Institute/MedAll requires CE faculty to disclose to the participants:

1. When products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and

2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Learning objectives

Understand the differences in effectiveness between first-line antidepressants in the treatment of Major Depressive Disorder (MDD).
Learn about factors to consider in selecting the right medication for MDD patients, including previous medication trials, family history, level of adherence, and cost/availability of drugs.
Analyze a specific patient case to understand the application of selected treatment plan and track treatment response over a period of time.
Interpret the Montreal and Asberg Depression Rating Scale (MADRS), Hamilton Depression Rating Scale (HAM-D), and Patient Health Questionnaire (PHQ-9) as evaluation tools in measuring the progress of depression treatment.
Appreciate the importance of patient's feedback, doctor-patient relationship, clarity on expectations, sign of recovery in early stages, and ensure regular follow-up for a successful treatment outcome.

Generated by MedBot

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

Adam Meadows, MD Red pill or blue pill? Evaluating the effectiveness of first-line antidepressants in the treatment of Major Depressive DisorderCase Patient history “Sally” • 44 y/o female • Haitian immigrant • High-achieving executive • Married with 3 children • Early life emotional trauma and neglect • Post-partum depression after 1st child • Did well on Sertraline historicallyCase Treatment Plan • Medication: Escitalopram • Psychotherapy: Cognitive Behavioral Therapy (CBT) • Vocational: FMLA support and return-to-work planning • Other: outpatient transcranial magnetic stimulation (TMS)Case Treatment Response • MADRS 30 > 24 > 8 (over an 8 week period) • Successful return to work • Psychotherapeutic progress • Improved sense of resilience • Practicing more acceptance and flexibility • More “presence” and connection with family • Increased sense of spiritual awareness and meaningAntidepressant comparison study from The Lancet Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and ConditionsPatient Health Questionnaire (PHQ-9)Hamilton Depression Rating Scale (HAM-D)Montgomery & Asberg Depression Rating Scale (MADRS)Patient-specific factors for medication selection • Side effect profile • Drug-drug interactions • Previous medication trials • Family history of response • Level of adherence • Cost/availabilityMarkers of treatment response in early stages • Feedback from patients • Doctor-patient relationship • Clarity on expectations • Scores on evidence-based tools • Attendance at follow up appointments • Collateral from family members • Review of medication bottles / pharmacy recordsThank you Glenda Wrenn Gordon, MD, MSHP, DFAPA Health Equity in Depression TreatmentAntidepressant comparison study from The Lancet Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and ConditionsHamilton Depression Rating Scale (HAM-D)Montgomery & Asberg Depression Rating Scale (MADRS)Patient-specific factors for medication selection • Side effect profile • Drug-drug interactions • Previous medication trials • Family history of response • Level of adherence • Cost/availabilityMarkers of treatment response in early stages • Feedback from patients • Doctor-patient relationship • Clarity on expectations • Scores on evidence-based tools • Attendance at follow up appointments • Collateral from family members • Review of medication bottles / pharmacy recordsThank you